HOME >> BIOLOGY >> NEWS
New prostate cancer gene identified

Phoenix, August 8th, 2004-Researchers at the Translational Genomics Research Institute (TGen) have found a new way to speed the discovery of genes that suppress tumors, and in the process identified a gene that appears to be important in prostate cancer. The findings appeared today in the journal Nature Genetics.

The gene, not previously known to be a tumor suppressor, most likely plays a role in regulating and maintaining normal tissue organization. The researchers have shown that the gene, known as EphB2, is inactivated in prostate cancer. This is the first time abnormalities in the gene have been linked to cancer. They believe loss of the gene's function leads to disorganization of cells and also encourages the growth and survival of prostate cancer cells.

"This finding provides critical insight into the factors that cause prostate cancer, which can be used for development of additional diagnostics and therapeutics for prostate cancer," said Dr. Spyro Mousses, head of TGen's Cancer Drug Development Laboratory and the paper's senior author. "Much additional research is warranted to determine the extent of its involvement in prostate cancer and other cancers as well."

"These findings represent a significant advancement in prostate cancer research, as the number of current treatment options for advanced prostate cancer remains limited," said Dr. John Carpten, Senior Investigator at TGen, Director of its Genetic Basis of Human Disease Division, and Head of the TGen Prostate Cancer Research Unit. "The discovery of mutations in this gene allows us the opportunity to explore a new path towards treating a significant number of men with advanced prostate cancer. As TGen's mission is to translate laboratory findings into the clinic, we hope to use this information to ultimately help provide prostate cancer patients more treatment options and a better quality of life."

The study was the result of an increasing trend in genome resea
'"/>

Contact: Candice Nulsen
cnulsen@tgen.org
The Translational Genomics Research Institute
8-Aug-2004


Page: 1 2

Related biology news :

1. Lycopene slows human prostate tumour growth in mice and combined with vitamin E is even better
2. Researchers identify distinctive signature for metastatic prostate cancer
3. Charting the future in prostate cancer care: A call to action
4. Study reveals first genetic step necessary for prostate cancer growth
5. Study narrows search for genes placing men at increased risk for prostate cancer
6. MICs shed light on prostate cancer
7. Alterations in vitamin D receptor gene increase prostate, breast cancer risk
8. U-M scientists find common virus in human prostate tissue
9. Newly designed nanoparticle quantum dots simultaneously target and image prostate tumors in mice
10. Gene expression patterns may help predict risk and progression of prostate cancer
11. Muscle-derived cells and gene therapy may cure for post-prostatectomy erectile dysfunction

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New prostate cancer gene identified

(Date:7/21/2015)... , July 21, 2015  NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... wallet, announces that it has filed provisional patent ... Method. This invention highlights next ... authorizes an account, but also the user using ...
(Date:7/13/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... on the growing mobile commerce market, announced today ... BEHAVIORAL-DIRECTED AUTHENTIATION METHOD AND SYSTEM. ... method to make payments.  With this patent, NXT-ID ... its groundbreaking voice-direct payment patent application, with behavior-directed ...
(Date:7/9/2015)... Calif. , July 9, 2015 /PRNewswire/ ... leading developer of human interface solutions, today ... the industry,s first fully hardware encapsulated fingerprint ... secure authentication technology is literally off the ... and biometric matching within the fingerprint sensor ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3
(Date:7/31/2015)... ... July 31, 2015 , ... Global ... and premium industry insights on the global resorcinol industry. The report highlights the ... of vivid market scenarios and analysis of primary and secondary inputs from the ...
(Date:7/30/2015)... , July 30, 2015   GenoSpace ... for the interpretation and analysis of genomic and ... Fischer has joined the company as Vice ... - http://photos.prnewswire.com/prnh/20150730/250931 "GenoSpace ... to integrate, interpret, analyze and explore complex sets ...
(Date:7/30/2015)... 30, 2015   Aratana Therapeutics, Inc . ... focused on the licensing, development and commercialization of ... that its strategic partner VetStem Biopharma, Inc. has ... of AT-016, an adipose-derived allogeneic stem cell product ... osteoarthritis pain in dogs. The double-blinded, ...
(Date:7/30/2015)... 2015  Discovery Laboratories, Inc. (Nasdaq: DSCO ... second $1.0M tranche under a previously awarded Phase ... at up to $3.0 million to support continued ... a potential medical countermeasure to mitigate acute and ... an initial $1.0 million under this grant in ...
Breaking Biology Technology:Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3
Cached News: